Archibald takes on a common question about low retatrutide doses and the drug's glucagon action. His view, not settled science, and retatrutide is still unapproved.
Recap by typeshit. Full story at Regan Archibald.
Researchers are starting to explain the shifts in libido some GLP-1 users report. The full story covers what scientists have found so far.
Bikman says the added glucagon receptor push raises energy use and liver fat burning, and points to 24.2% weight loss on 12 mg in phase 2.
A report says an Eli Lilly drug helped protect muscle mass when combined with Novo's Wegovy, addressing a common worry about lean mass loss.
He says close to 40% of weight lost in the trial's body-scan group was lean mass, and argues muscle loss isn't the drug's fault.
She walks through the phase 3 data, including knee osteoarthritis results, and explains why she calls online reta vials a gamble.
In a Healio Eye-Mail brief, she gives her view on a review of a possible link between GLP-1 medications and NAION, a type of optic nerve damage.
Loading…